Collegium Pharmaceutical Announces 2026 Revenue Outlook and $650M AZSTARYS Acquisition
Collegium Pharmaceutical (NASDAQ:COLL) provided its 2026 revenue outlook, projecting $805M–$825M in total revenue, and announced a $650M acquisition of the ADHD treatment AZSTARYS from Corium. The deal includes up to $135M in milestones and is expected to be immediately accretive.
Tickers: $COLL
Topics: acquisition ADHD treatment financial performance pharmaceutical revenue guidance